Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marit J van Gils

Showing results (1-10 of 221) with videos related to

Pageof 23
Sort By:
Current HIV Research|November 9, 2010
Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?Marit J van Gils, Hanneke Schuitemaker
The Journal of Biological Chemistry|September 3, 2017
Opposites attract in bispecific antibody engineeringMarit J van Gils, Rogier W Sanders
Immunity|July 19, 2018
Hitting HIV's HarpoonMarit J van Gils, Rogier W Sanders
Retrovirology|November 28, 2018
HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadthJelle van Schooten, Marit J van Gils
Virology|December 11, 2012
Broadly neutralizing antibodies against HIV-1: templates for a vaccineMarit J van Gils, Rogier W Sanders
Trends in Microbiology|August 30, 2014
In vivo protection by broadly neutralizing HIV antibodiesMarit J van Gils, Rogier W Sanders
Current Opinion in Virology|August 18, 2019
The potential of engineered antibodies for HIV-1 therapy and cureMarloes Grobben, Richard Al Stuart, Marit J van Gils
Frontiers in Immunology|January 7, 2022
Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and PreventionKshitij Wagh, Marit J van Gils, Harry Gristick, et al.
AIDS (London, England)|September 23, 2009
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progressionMarit J van Gils, Zelda Euler, Becky Schweighardt, et al.
Pharmacological Research|June 23, 2020
Ephrin-Eph signaling usage by a variety of virusesEsther C W de Boer, Janine M van Gils, Marit J van Gils
Pageof 23

Showing results (1-10 of 221) with videos related to

Sort By:
Pageof 23
Current HIV Research|November 9, 2010
Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?Marit J van Gils, Hanneke Schuitemaker
The Journal of Biological Chemistry|September 3, 2017
Opposites attract in bispecific antibody engineeringMarit J van Gils, Rogier W Sanders
Immunity|July 19, 2018
Hitting HIV's HarpoonMarit J van Gils, Rogier W Sanders
Retrovirology|November 28, 2018
HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadthJelle van Schooten, Marit J van Gils
Virology|December 11, 2012
Broadly neutralizing antibodies against HIV-1: templates for a vaccineMarit J van Gils, Rogier W Sanders
Trends in Microbiology|August 30, 2014
In vivo protection by broadly neutralizing HIV antibodiesMarit J van Gils, Rogier W Sanders
Current Opinion in Virology|August 18, 2019
The potential of engineered antibodies for HIV-1 therapy and cureMarloes Grobben, Richard Al Stuart, Marit J van Gils
Frontiers in Immunology|January 7, 2022
Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and PreventionKshitij Wagh, Marit J van Gils, Harry Gristick, et al.
AIDS (London, England)|September 23, 2009
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progressionMarit J van Gils, Zelda Euler, Becky Schweighardt, et al.
Pharmacological Research|June 23, 2020
Ephrin-Eph signaling usage by a variety of virusesEsther C W de Boer, Janine M van Gils, Marit J van Gils
Pageof 23